Article
Effect of apolipoprotein E, peroxisome proliferator-activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients.
Pharmacogenetics - 1 Jun 2002
Brisson Diane, Ledoux Karine, Bossé Yohan, St-Pierre Julie, Julien Pierre, Perron Patrice, Hudson Thomas J, Vohl Marie-Claude, Gaudet Daniel
Abstract excerpt
Fenofibrate is a peroxisome proliferator-activated receptor alpha (PPARalpha) agonist which regulates the transcription of genes encoding proteins involved in triglyceride (TG)-rich lipoproteins and lipoprotein lipase (LPL) metabolism. The aim of the present study was to investigate the relation between TG-related parameters considered in different clinical guidelines used in industrialized countries for the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
